| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | RP46; H-IDHB |
| WB Predicted band size | 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human IDH3B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IDH3B抗体的3篇参考文献及其简要摘要：
1. **"IDH3B mutations alter cellular metabolism and sensitize glioblastoma to targeted therapy"**
*Author: Smith J, et al. (2022)*
摘要：研究探讨了IDH3B突变在胶质母细胞瘤中的代谢重编程作用，开发了一种特异性抗体用于检测突变蛋白表达，并验证其作为潜在治疗靶点的可能性。
2. **"Antibody-based detection of IDH3B in mitochondrial dysfunction studies"**
*Author: Lee S, et al. (2020)*
摘要：报道了一种高灵敏度的IDH3B单克隆抗体的制备，应用于线粒体功能异常的细胞模型中，揭示IDH3B缺失与氧化应激的相关性。
3. **"IDH3B as a biomarker in clear cell renal cell carcinoma: validation via immunohistochemistry"**
*Author: García-Ruiz C, et al. (2019)*
摘要：通过商业化IDH3B抗体进行免疫组化分析，发现IDH3B在肾透明细胞癌中表达显著下调，提示其作为预后标志物的潜在价值。
注：上述文献为示例，实际引用需根据具体研究通过学术数据库(如PubMed、Web of Science)核实。如需查找真实文献，建议结合关键词“IDH3B antibody”“IDH3B function”检索近年论文。
The IDH3B antibody is a crucial tool for studying the isocitrate dehydrogenase 3 beta subunit (IDH3B), a component of the IDH3 enzyme complex within the tricarboxylic acid (TCA) cycle. IDH3 catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), a reaction essential for cellular energy production and redox balance. Unlike the NADP-dependent IDH1 and IDH2 isoforms, IDH3 is NAD+-dependent and functions exclusively in mitochondria. IDH3B, encoded by the *IDH3B* gene, forms a heterotetramer with IDH3A and IDH3G subunits, and its expression is critical for maintaining metabolic homeostasis.
Mutations in IDH family genes, particularly *IDH1* and *IDH2*, are well-documented in cancers such as gliomas and acute myeloid leukemia (AML), where they drive oncogenesis via 2-hydroxyglutarate (2-HG) accumulation. While IDH3B alterations are less commonly implicated in cancer, recent studies suggest its potential role in metabolic reprogramming and tumorigenesis. The IDH3B antibody enables the detection and quantification of IDH3B protein levels in tissues or cells, aiding research on mitochondrial dysfunction, metabolic disorders, and cancer biology.
Clinically, IDH3B antibodies are used in immunohistochemistry (IHC), Western blotting, and ELISA to assess protein expression patterns, offering insights into disease mechanisms or therapeutic responses. Their application extends to exploring IDH3B's regulatory roles in cellular differentiation, apoptosis, and oxidative stress. As interest in metabolic enzymes as therapeutic targets grows, IDH3B antibodies remain vital for elucidating the complex interplay between mitochondrial metabolism and disease.
×
